Pfizer (PFE) Wins TUKYSA Approval And LITFULO Data, Is It Still 3% Undervalued?
Pfizer (PFE) Wins TUKYSA Approval And LITFULO Data, Is It Still 3% Undervalued? Simply Wall Street
Covered in this story
Analyst targets on Pfizer
- Scotiabank: $27.5 → $33 by Oct 2027 · Sector Outperform via GuruFocus
- BMO Capital Markets: $27.3 → $30 by Aug 2027 · Buy via 富途牛牛
- HSBC: $23.7 → $28 by Jul 2027 · Hold via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 48 stories mentioning Pfizer, the earliest published 18 Jun 2026.
Summary aggregated from Simply Wall Street's public RSS feed. The full reporting belongs to Simply Wall Street — please read it on their site.